How GHK-Cu interacts with cells
The proposed mechanism in outline
GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine. The proposed mechanism starts from chemistry: the GHK tripeptide binds copper(II) tightly, and the question is what that binding does once the complex meets cells. Two ideas run through the literature. One is that GHK acts as a carrier that delivers copper into cells. The other is that the complex acts as a signalling molecule that changes gene expression and cell behaviour. The published work does not settle which, or whether both are true.
What the compound is and how it is classified is on the GHK-Cu identity page. The literature as a whole is reviewed by evidence tier in the GHK-Cu research review. This page is only about how it is proposed to work.
Molecular targets
There is no single established receptor for GHK-Cu. The targets below are of two kinds: a metal-binding site, which is chemistry, and candidate protein targets, which are single-study proposals.
Primary target: copper(II) itself
Structural work using X-ray crystallography, EPR, NMR and X-ray absorption spectroscopy (Hureau and colleagues, 2011) shows copper(II) held by the amino group, a deprotonated amide nitrogen and the imidazole nitrogen of the histidine. In solution the complex is a monomer with a labile fourth coordination site, which a carboxylate oxygen occupies in the solid state. Under moderate redox conditions it is inert, but it can be reduced to copper(I) at about −0.62 V against Ag/AgCl, after which copper is released.
The earlier biological observation (Pickart and colleagues, Nature, 1980) is that the tripeptide forms complexes with copper(II) and enhanced copper uptake into cultured hepatoma cells. The authors drew the parallel with copper-transport sites on albumin and alpha-fetoprotein, and proposed a transport role.
Candidate protein targets, and the systems they came from
| Candidate | System | Basis |
|---|---|---|
| SIRT1 | C2C12 muscle cells and mice exposed to cigarette smoke (2023) | Reported binding and activation, with a computed docking energy of −6.1 kcal/mol |
| SIRT1 and STAT3 signalling | Mice with chemically induced colitis and a mouse cell co-culture (2025) | Target predicted by network pharmacology and docking, then probed by protein expression and gene silencing |
| Peroxiredoxin 6 | Mice with silica-induced lung inflammation and a macrophage cell line (2024) | Reported to bind the protein |
All three are cell or mouse systems, and each comes from a single group using an induced-disease model. SIRT1 recurs, which is interesting, but docking energies and expression changes are suggestive rather than proof of a binding site, and none has been independently replicated in the sources cited here.
A separate line of work uses gene-expression databases to ask which genes the tripeptide is associated with. That is a computational association, reported by authors who work for a skin-biology company (Pickart and Margolina, 2018), and it does not identify a molecular target.
Demonstrated versus inferred
| Statement | Evidence tier | Status |
|---|---|---|
| GHK binds copper(II), with defined coordination geometry | Chemistry, in solution and solid state | Demonstrated |
| The complex can be reduced to copper(I) with release of copper | Chemistry, electrochemical | Demonstrated under the conditions tested |
| GHK enhances copper uptake into cultured cells | In vitro, hepatoma cells, 1980 | Reported, single system |
| The complex stimulates collagen synthesis in fibroblast cultures | In vitro, 1988 | Reported, effect seen from about 10⁻¹² M and maximal near 10⁻⁹ M |
| GHK-Cu binds and activates SIRT1 | Cell and mouse, with docking | Proposed, single group |
| GHK-Cu acts through a defined pathway in human tissue | Human | Not established |
The last row is the honest summary. The mechanism has been described in tubes, dishes and mice, and there is no human study that tests it.
What the copper contributes
Free GHK without copper is a tripeptide with a copper-binding site. With copper bound it is a metal complex with its own geometry and redox behaviour. Whether biological effects reported for the complex are due to the peptide, the copper, or the combination is not separated by most of the literature, because most studies use the complex and do not run a copper-free control.
Copper(II) complexes are typically coloured, usually blue to violet, because of electronic transitions of the metal ion in its coordination environment. That is a property of the chemistry. It is not a test of identity or purity, and colour alone cannot tell a reader which peptide is bound to the copper. Identity is established by a batch certificate.
How this differs from adjacent compounds
The contrast is in molecular architecture, not in a product comparison.
| Compound | What it is | Metal binding |
|---|---|---|
| GHK-Cu | Three-residue peptide, supplied as its copper(II) complex | Defining feature |
| AHK-Cu | Copper complex of a different tripeptide, alanyl-L-histidyl-L-lysine | Also copper-binding, different peptide |
| BPC-157 | Synthetic 15-residue peptide | Not a metal complex |
| TB-500 | Synthetic fragment of thymosin beta-4 | Not a metal complex |
"Copper peptide" is a class name, not a compound. Evidence for one copper-binding peptide does not transfer to another. GHK-Cu is also one of the four components of the KLOW research blend, where it is quantified separately from the other three.
Open questions
- Carrier or signal. Whether GHK is mainly a copper-delivery molecule or a signalling ligand has not been resolved.
- Copper-free controls. The contribution of the peptide alone, as against the complex, is rarely isolated.
- Independent replication. The founding work and several reviews come from one research group. Recent target studies are single-laboratory.
- Human relevance. No cited study tests the proposed pathways in people.
- Research reagent versus the studied material. Published work describes the material its authors used. Whether a given batch matches it is a question of identity and purity, which is what the COA publication status addresses.
EPS documentation
Use the research catalogue to check the exact name, labelled amount and format. The COA library publishes the original Janoshik reports selected for EPS, retaining the original report client name and any missing batch fields. Literature findings and another supplier's analytical results are not evidence about an EPS batch.
References
- Pickart L, Freedman JH, Loker WJ, et al. Growth-modulating plasma tripeptide may function by facilitating copper uptake into cells. Nature. 1980;288(5792):715-717.
- Maquart FX, Pickart L, Laurent M, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988;238(2):343-346.
- Hureau C, Eury H, Guillot R, et al. X-ray and solution structures of Cu(II) GHK and Cu(II) DAHK complexes: influence on their redox properties. Chem Eur J. 2011;17(36):10151-10160.
- Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987.
- Deng M, Zhang Q, Yan L, et al. Glycyl-L-histidyl-L-lysine-Cu2+ rescues cigarette smoking-induced skeletal muscle dysfunction via a sirtuin 1-dependent pathway. J Cachexia Sarcopenia Muscle. 2023;14(3):1365-1380.
- Bian Y, Deng M, Liu J, et al. The glycyl-L-histidyl-L-lysine-Cu2+ tripeptide complex attenuates lung inflammation and fibrosis in silicosis by targeting peroxiredoxin 6. Redox Biol. 2024;75:103237.
- Mao S, Huang J, Li J, et al. Exploring the beneficial effects of GHK-Cu on an experimental model of colitis and the underlying mechanisms. Front Pharmacol. 2025;16:1551843.
